Navigation Links
Collexis Achieves 200,000 Registered Users

COLUMBIA, S.C., Aug. 19 /PRNewswire-FirstCall/ -- Collexis Holdings, Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic technology and knowledge discovery software, announced today that their life science research portal has surpassed the 200,000 registered user mark .


"Achieving 200,000 registered users in less than 18 months is very positive and we expect that the fall research season will continue to allow BiomedExperts to grow at a healthy pace," stated Bill Kirkland, CEO of Collexis. "We are very excited about our latest partnership with the American Institute of Physics and the pending publishing partnerships that are on the horizon. Further our plans to launch additional functionality over the course of the year will only enhance BiomedExpert's position in the life science industry."

"We continue to hear great things about BiomedExperts from the life science community," states Dr. Christian Herzog, M.D., Managing Director for Collexis STM markets. "BiomedExperts has established itself as the social media tool for life science researchers to be seen and to find new collaborators."

Pre-populated with over 1.8 million Pub-Med-based expert profiles, BiomedExperts allows scientists and researchers to directly connect with and explore their own professional contacts, grow their networks and identify researchers with the expertise needed for future collaborations. Through user-friendly search interfaces, potential research collaborators can share data and collaborate with professionals from more than 1,800 organizations and institutions from 137 countries, totaling more than 30 million connections made through the site.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic technology and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio, Cologne, Germany and Valparaiso, Chile. Collexis now offers the world's first pre-populated scientific social network for life science researchers, Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-K for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

SOURCE Collexis Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year!
2. Collexis Launches Innovative Reviewer Finder to Enhance the $30 Billion Health Research Grant Industry
3. Collexis Healthcare to Expand Capabilities for Asklepios Group Utilizing Microsoft Solutions
4. Mayo Clinic to Pilot Collexis Expert Profiling
5. InfoLogix Achieves Motorola Enterprise Mobility Validation
6. ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician
7. BioNeutrals Ygiene(TM) Achieves Worlds Fastest Kill Time With a 100% Total Spore Eradication Verified In Independent Sporicidal/Sterilant Test
8. Germgards New Room-Temperature Surgical Instrument Sterilizer Achieves Total Cycle Time of Three Minutes
9. Established Medical Sub-Component Manufacturer Achieves ISO 13485 Certification
10. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
11. DST Health Solutions Achieves ISO 9001:2008 Certification
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology: